Global Leading Market Research Publisher QYResearch announces the release of its latest report “Sodium Hyaluronate Eye Drops – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart):
https://www.qyresearch.com/reports/4798548/sodium-hyaluronate-eye-drops
To Ophthalmic Pharmaceutical Executives, Eye Care Product Managers, and Healthcare Investors:
If your organization develops or markets products for dry eye disease, post-operative ocular repair, or general eye discomfort, you face a persistent challenge: meeting the growing demand for effective, safe, and comfortable ophthalmic lubricants. The global incidence of dry eye disease is increasing due to aging populations, prolonged electronic device use, and environmental factors. The solution lies in sodium hyaluronate eye drops —ophthalmic drugs with sodium hyaluronate as the core ingredient, a viscoelastic substance and natural high-molecular polysaccharide that forms a protective film to lubricate the ocular surface, absorbs and locks in water (water absorption capacity up to 1,000 times its own weight), maintains tear film stability, promotes migration and proliferation of corneal epithelial cells, accelerates damage repair, and inhibits inflammatory reactions. According to QYResearch’s newly released market forecast, the global sodium hyaluronate eye drops market was valued at US$307 million in 2024 and is projected to reach US$456 million by 2031, growing at a compound annual growth rate (CAGR) of 5.8 percent during the 2025-2031 forecast period. This steady growth reflects the high and rising incidence of dry eye disease, accelerating global aging, consumption upgrades toward preservative-free formulations, and clinical recognition of sodium hyaluronate as a first-line treatment.
1. Product Definition: Viscoelastic Ocular Lubricant and Corneal Repair Agent
Sodium hyaluronate eye drops are ophthalmic drugs with sodium hyaluronate as the core ingredient. Sodium hyaluronate is a viscoelastic substance—a natural high-molecular polysaccharide (a glycosaminoglycan) found naturally in the vitreous humor of the eye, synovial fluid, and connective tissues. When applied as eye drops, sodium hyaluronate provides multiple therapeutic benefits: lubrication (forms a protective film on the ocular surface, reducing friction between the eyelid and cornea during blinking), water retention (absorbs and locks in water up to 1,000 times its own weight, maintaining corneal hydration), tear film stabilization (improves the stability of the tear film, reducing tear breakup time), corneal epithelial cell migration and proliferation (promotes healing of corneal abrasions and epithelial defects), acceleration of damage repair (following cataract surgery, refractive surgery, or corneal injury), and anti-inflammatory effects (inhibits inflammatory reactions on the ocular surface).
The market is segmented by sodium hyaluronate concentration into 0.1 percent (low concentration, for mild dry eye and general lubrication), 0.15 percent (medium concentration, for moderate dry eye and post-operative use), 0.3 percent (high concentration, for severe dry eye, advanced corneal repair, and premium product positioning), and others. The 0.1 percent concentration currently represents the largest segment (approximately 40 percent of revenue), as it is suitable for most mild-to-moderate dry eye patients. The 0.3 percent concentration is the fastest-growing segment (approximately 8-9 percent CAGR), driven by demand for higher-viscosity, longer-lasting lubrication in severe dry eye and post-surgical applications.
By application, the market serves dry eye (the largest segment, approximately 50-55 percent of revenue), rewetting (refreshing eye drops for contact lens users or those with occasional discomfort), and others (post-operative care following cataract or refractive surgery, corneal abrasion treatment, environmental exposure protection). Dry eye dominates due to the high global prevalence of the condition.
2. Key Market Drivers: Disease Spectrum Changes, Aging, and Consumption Upgrade
The sodium hyaluronate eye drops market is driven by three primary forces: the high and rising incidence of dry eye disease, accelerating global aging, and consumption upgrades toward preservative-free and natural ingredient products.
A. High Incidence of Dry Eye Disease
The global incidence of dry eye disease ranges from 5 to 35 percent depending on the population studied and diagnostic criteria used. In China, the prevalence rate among urban populations exceeds 30 percent , driven by several factors: prolonged use of electronic devices (average daily screen time exceeds 8 hours for many office workers, reducing blink rate and increasing tear evaporation), dry indoor environments (air conditioning, heating, low humidity), extensive contact lens use, and increasing prevalence of conditions associated with dry eye (Sjögren’s syndrome, meibomian gland dysfunction, blepharitis). According to The Ocular Surface Society 2025 data, dry eye disease affects approximately 350 million people globally. Sodium hyaluronate eye drops, with their water-retention and tear-film-stabilizing properties, are a first-line treatment for dry eye.
B. Accelerating Global Aging
In 2025, the global population over 65 years old exceeded 1 billion , according to United Nations data. Aging is associated with increased dry eye prevalence (tear production decreases with age, meibomian gland function declines, and eyelid laxity increases). Additionally, the number of patients with age-related eye conditions (senile cataracts, glaucoma) is increasing, driving demand for post-operative repair eye drops following cataract surgery and other ocular procedures. Sodium hyaluronate eye drops are commonly prescribed after cataract surgery to promote corneal healing, reduce inflammation, and improve patient comfort. A user case from an ophthalmology clinic (documented in Q1 2025) reported that prescribing 0.3 percent sodium hyaluronate eye drops for one week following cataract surgery reduced patient-reported post-operative discomfort scores by 40 percent and accelerated visual recovery by 2 days compared to standard artificial tears.
C. Consumption Upgrade and Health Awareness
Younger consumers (Generation Z and millennials) have a stronger preference for ”preservative-free” and ”natural ingredients” products, driving the growth of the high-end eye drops market (such as 0.3 percent concentration, daily disposable single-dose units). Preservatives (such as benzalkonium chloride, BAK) in multi-dose eye drop bottles can cause ocular surface toxicity with prolonged use, exacerbating dry eye symptoms. Preservative-free, single-dose units (often 0.4-0.8 mL per unit, used once and discarded) eliminate preservative exposure, making them preferred for chronic use. A user case from a retail pharmacy chain (documented in Q4 2024) reported that sales of preservative-free sodium hyaluronate eye drops grew 35 percent year-over-year, compared to 5 percent growth for preserved multi-dose bottles, with younger consumers (under 35) accounting for 60 percent of preservative-free purchases.
Clinical recognition has also driven market growth: sodium hyaluronate eye drops have been included in the ”China Dry Eye Diagnosis and Treatment Guidelines” as a first-line treatment drug, and similar recognition exists in international guidelines (TFOS DEWS II, Asia Dry Eye Society guidelines). This clinical validation increases physician prescribing and patient trust.
Exclusive Analyst Observation (Q2 2025 Data): The sodium hyaluronate eye drops market shows a clear parallel trend of “high-end + popularization.” In developed markets (North America, Western Europe, Japan), the market is shifting toward premium products: higher concentrations (0.3 percent), preservative-free single-dose units, and compound formulations (sodium hyaluronate with vitamin B12, taurine, or other additives for enhanced anti-fatigue effects). In emerging markets (China, India, Southeast Asia, Latin America), the market is expanding in volume with lower-concentration (0.1-0.15 percent), preserved multi-dose bottles at lower price points. International companies (URSAPHARM, Santen, Bayer, Bausch & Lomb, Johnson & Johnson, Alcon, Rohto, Thea Pharmaceuticals, Allergan) dominate the high-end market with their technological advantages (proprietary formulations, preservative-free packaging systems, clinical evidence). Domestic companies (The United Laboratories, Bloomage Biotechnology in China; others in India, Brazil) are gaining market share through cost advantages (lower manufacturing and regulatory costs) and innovation capabilities (developing competitive formulations). Global top five manufacturers hold approximately 40 percent of market share, indicating a moderately fragmented market.
3. Regional Market Dynamics
Asia-Pacific is the largest market , with a share over 45 percent , driven by high dry eye prevalence in China, Japan, South Korea, and India, large aging populations, and increasing consumer awareness. North America and Europe together account for over 35 percent of market share, driven by established dry eye diagnosis and treatment practices, high healthcare spending, and premium product adoption. The Rest of World (Latin America, Middle East, Africa) represents the remaining share, with significant growth potential as healthcare infrastructure develops.
4. Technological Progress and Product Iteration
The sodium hyaluronate eye drops market is characterized by ongoing technological progress and product iteration. Formula optimization has moved from single sodium hyaluronate to compound formulas (such as adding vitamin B12 for nerve protection and anti-fatigue effects, taurine for antioxidant and cell membrane stabilization, or other lubricants like carboxymethylcellulose). Dosage form innovation has introduced daily disposable independent packaging (such as 0.3 percent sodium hyaluronate single-dose units), which reduces preservative irritation, improves patient compliance, and commands premium pricing. Future product iteration and compliance operations (ensuring consistent quality and regulatory adherence) will become core competitiveness factors.
5. Market Outlook 2025-2031 and Strategic Recommendations
Based on QYResearch forecast models, the global sodium hyaluronate eye drops market will reach US$456 million by 2031 at a CAGR of 5.8 percent.
For ophthalmic pharmaceutical executives: Develop preservative-free, single-dose unit formulations for developed markets where consumers prioritize safety and comfort. Develop cost-effective, preserved multi-dose bottles for emerging markets where price sensitivity is high. Consider compound formulations (sodium hyaluronate + vitamin B12, + taurine) for product differentiation.
For marketing managers: Position sodium hyaluronate eye drops not as “artificial tears” but as corneal protective and reparative agents that treat the pathophysiology of dry eye, not just symptoms. Emphasize water-binding capacity (1,000x own weight), clinical guideline recommendations, and preservative-free options.
For investors: Companies with strong positions in preservative-free single-dose technology (URSAPHARM, Santen, Alcon, Thea Pharmaceuticals), high-concentration (0.3 percent) products, and presence in high-growth Asia-Pacific markets are positioned for above-market growth.
Key risks to monitor include generic competition (as patents expire, generic sodium hyaluronate eye drops may erode prices), competition from alternative dry eye treatments (cyclosporine A (Restasis), lifitegrast (Xiidra), varenicline nasal spray (Tyrvaya), punctual plugs), and regulatory changes affecting preservative use or OTC classification.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
